Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Comorbidities Clear all
Completed No phase listed Observational

Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI

NCT03434561
View directory record Official record
Conditions
Hematopoietic Malignancy
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
20 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 24, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Comprehensive Care of Cancer Patients

NCT05323409
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
Interventions
OPTIMISE
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Not yet recruiting Not applicable Interventional

Theoretically Informed Behavioral Intervention

NCT06580184
View directory record Official record
Conditions
HIV, CVD, Metabolic Disease
Interventions
LEARN 2 Platform
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care

NCT07461493
View directory record Official record
Conditions
Cancer, Cancer Comorbidities
Interventions
Not listed
Lead sponsor
National Minority Quality Forum
Other
Eligibility
35 Years and older
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2039
U.S. locations
2
States / cities
Flint, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Completed No phase listed Observational

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)

NCT03992352
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Age 60+ with planned HCT for Hematologic Malignancy
Diagnostic Test
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
60 Years and older
Enrollment
1,229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
50
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

NCT02315768
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
GA101, Ibrutinib
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

NCT01832922
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jul 24, 2026, 1:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321
View directory record Official record
Conditions
Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
Interventions
Isatuximab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

NCT02053610
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806
View directory record Official record
Conditions
Hodgkin Disease, Peripheral T Cell Lymphoma
Interventions
brentuximab vedotin, bendamustine, dacarbazine, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 24, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional Results available

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Dutasteride, Finasteride, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

NCT01010061
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 24, 2026, 1:09 AM EDT
Completed No phase listed Observational

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

NCT01930981
View directory record Official record
Conditions
Hematologic Malignancies, Other Diagnoses, Comorbidities, and Complications
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Jul 24, 2026, 1:09 AM EDT
Terminated Phase 2 Interventional

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

NCT00251186
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine and Cetuximab
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Jul 24, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587
View directory record Official record
Conditions
Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Interventions
Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel, Docetaxel, Gemcitabine, Etoposide, Irinotecan, Topotecan, Lurbinectedin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Steps to Eliminate Postoperative Problems

NCT02880176
View directory record Official record
Conditions
Bladder Cancer
Interventions
Financial Incentive to Increase Ambulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 24, 2026, 1:09 AM EDT
Completed No phase listed Observational

Aging and Cancer Effects (ACE) Study

NCT00204880
View directory record Official record
Conditions
Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Not applicable Interventional

Comorbidities And Reducing inEquitieS

NCT04836221
View directory record Official record
Conditions
Cancer, Breast, Diabetes Mellitus, Hypertension, Cancer Prostate
Interventions
Support
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

NCT01998880
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
obinutuzumab, rituximab, chlorambucil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 24, 2026, 1:09 AM EDT
Active, not recruiting No phase listed Observational

Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

NCT01030250
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 24, 2026, 1:09 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Jul 24, 2026, 1:09 AM EDT